Search for a trial

Molecular markers in biomaterial derived from patients with inflammatory bowel disease

Systematic gathering of biomaterial and phenotypic data of IBD patients during clinical care provides assessment of molecular markers in the DNA, the transcriptome and proteome. The markers can be associated with the different disease phenotypes…

Clinical Performance Study Plan (CPSP) for the use of GenDx CDx Tedopi for subject enrollment on to the OSE Immunotherapeutics Phase 3 trial (OSE2101C302) of OSE2101 versus docetaxel in HLA-A*02 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to immune checkpoint inhibitor (ARTEMIA)

This clinical performance study/clinical investigation will evaluate the safety and effectiveness of GenDx CDx Tedopi in identifying HLA-A*02 status in metastatic NSCLC subjects who may be eligible for treatment with OSE2101.